Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoplasm, Breast|Breast Diseases|Antihypertensive Agents|Sacubitril/Valsartan|Angiotensin II Type 1 Receptor Blockers|Angiotensin Receptor Antagonists|Molecular Mechanisms of Pharmacological Action|Heart Failure|Cardiac Toxicity|Cancer, Therapy-Related|Cancer Therapy-Related Cardiac Dysfunction|Cardiotoxicity
Interventions: DRUG: Sacubitril-valsartan
Sponsor: Silesian Centre for Heart Diseases
Collaborators: Medical Research Agency, Poland